Immune Checkpoint Inhibitors (ICI 2018) is a conference dedicated to the pathway biology and biomarker strategy in the development of your checkpoint drugs.
Immune Checkpoint Inhibitors (ICI 2018) covers topics such as:
- Immuno-oncology combinations that deliver more robust and durable patient responses
- Discovery and validation of pathway biologies beyond PD-1
- The commercial strategy of the most advanced players and assess market opportunities for the year to come
- Novel biomarkers for patient stratification
- New preclinical models that effectively recapitulate the human immune system and improve predictability into the clinic
- Clinical strategies that support the rapid generation of trial data and support appropriate registrational paths
- Novel research on the TME, immune ecosystem and how these factors influence efficacy
